{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T03:29:29Z","timestamp":1789702169814,"version":"4.0.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"25","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,6,19]],"date-time":"2015-06-19T00:00:00Z","timestamp":1434672000000},"content-version":"am","delay-in-days":414,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23591475"],"award-info":[{"award-number":["23591475"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004532","name":"Japan International Cooperation Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004532","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.vaccine.2014.03.022","type":"journal-article","created":{"date-parts":[[2014,3,22]],"date-time":"2014-03-22T20:45:24Z","timestamp":1395521124000},"page":"3066-3074","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Oral administration of genetically modified Bifidobacterium displaying HCV-NS3 multi-epitope fusion protein could induce an HCV-NS3-specific systemic immune response in mice"],"prefix":"10.1016","volume":"32","author":[{"given":"Saki","family":"Takei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chika","family":"Omoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takane","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumi","family":"Shigemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Kawabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hak","family":"Hotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiro","family":"Shirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"46","key":"10.1016\/j.vaccine.2014.03.022_bib0005","first-page":"341","article-title":"Hepatitis C: global prevalence","volume":"72","author":"World Health Organization","year":"1997","journal-title":"Wkly Epidemiol Rec"},{"issue":"17","key":"10.1016\/j.vaccine.2014.03.022_bib0010","doi-asserted-by":"crossref","first-page":"8239","DOI":"10.1073\/pnas.91.17.8239","article-title":"Sequence analysis of the core gene of 14 hepatitis C virus genotypes","volume":"91","author":"Bukh","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7350","key":"10.1016\/j.vaccine.2014.03.022_bib0015","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/474S1a","article-title":"Hepatitis C","volume":"474","author":"Brody","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.vaccine.2014.03.022_bib0020","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00281-012-0332-x","article-title":"Innate immune responses in hepatitis C virus infection","volume":"35","author":"Li","year":"2013","journal-title":"Semin Immunopathol"},{"issue":"5 Suppl 1","key":"10.1016\/j.vaccine.2014.03.022_bib0025","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1002\/hep.1840360716","article-title":"Optimal therapy of hepatitis C","volume":"36","author":"Di Bisceglie","year":"2002","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.vaccine.2014.03.022_bib0030","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.cgh.2012.10.006","article-title":"Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection","volume":"11","author":"Flamm","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.vaccine.2014.03.022_bib0035","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jhep.2011.07.016","article-title":"Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan","volume":"56","author":"Kumada","year":"2012","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.vaccine.2014.03.022_bib0040","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.bpg.2012.09.001","article-title":"Triple therapy with boceprevir or telaprevir for treatment na\u00efve HCV patients","volume":"26","author":"Esteban","year":"2012","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"6","key":"10.1016\/j.vaccine.2014.03.022_bib0045","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.jhep.2010.09.040","article-title":"Progress in the development of preventive and therapeutic vaccines for hepatitis C virus","volume":"54","author":"Torresi","year":"2011","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.vaccine.2014.03.022_bib0050","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1128\/JVI.74.4.2046-2051.2000","article-title":"Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3\u2019 nontranslated region are essential for virus replication in vivo","volume":"74","author":"Kolykhalov","year":"2000","journal-title":"J Virol"},{"issue":"Pt 6","key":"10.1016\/j.vaccine.2014.03.022_bib0055","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1099\/vir.0.79821-0","article-title":"Priming with CpG-enriched plasmid and boosting with protein formulated with CpG oligodeoxynucleotides and Quil A induces strong cellular and humoral immune responses to hepatitis C virus NS3","volume":"85","author":"Yu","year":"2004","journal-title":"J Gen Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2014.03.022_bib0060","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/jgm.1144","article-title":"Protective vaccination with hepatitis C virus NS3 but not core antigen in a novel mouse challenge model","volume":"10","author":"El-Gogo","year":"2008","journal-title":"J Gene Med"},{"issue":"2","key":"10.1016\/j.vaccine.2014.03.022_bib0065","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1172\/JCI117694","article-title":"Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif","volume":"95","author":"Cerny","year":"1995","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.vaccine.2014.03.022_bib0070","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijfoodmicro.2008.04.012","article-title":"Interaction of probiotic Lactobacillus and Bifidobacterium strains with human intestinal epithelial cells: adhesion properties, competition against enteropathogens and modulation of IL-8 production","volume":"125","author":"Candela","year":"2008","journal-title":"Int J Food Microbiol"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2014.03.022_bib0075","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijfoodmicro.2009.12.023","article-title":"Distinct Bifidobacterium strains drive different immune responses in vitro","volume":"138","author":"L\u00f3pez","year":"2010","journal-title":"Int J Food Microbiol"},{"issue":"19","key":"10.1016\/j.vaccine.2014.03.022_bib0080","doi-asserted-by":"crossref","first-page":"13165","DOI":"10.1074\/jbc.M709777200","article-title":"Structural and thermodynamic analyses of solute-binding protein from Bifidobacterium longum specific for core 1 disaccharide and lacto-N-biose I","volume":"283","author":"Suzuki","year":"2008","journal-title":"J Biol Chem"},{"issue":"41","key":"10.1016\/j.vaccine.2014.03.022_bib0085","doi-asserted-by":"crossref","first-page":"6684","DOI":"10.1016\/j.vaccine.2010.08.007","article-title":"Genetically modified Bifidobacterium displaying Salmonella-antigen protects mice from lethal challenge of Salmonella Typhimurium in a murine typhoid fever model","volume":"28","author":"Yamamoto","year":"2010","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2014.03.022_bib0090","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1271\/bbb.61.1211","article-title":"Construction of Escherichia coli\u2013Bifidobacterium longum shuttle vector transforming B. longum 105-A and 108-A","volume":"61","author":"Matsumura","year":"1997","journal-title":"Biosci Biotechnol Biochem"},{"issue":"7","key":"10.1016\/j.vaccine.2014.03.022_bib0095","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1128\/jvi.69.7.4373-4380.1995","article-title":"A central region in the hepatitis C virus NS4A protein allows formation of an active NS3-NS4A serine proteinase complex in vivo and in vitro","volume":"69","author":"Lin","year":"1995","journal-title":"J Virol"},{"issue":"11","key":"10.1016\/j.vaccine.2014.03.022_bib0100","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0969-2126(00)80025-8","article-title":"Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase","volume":"7","author":"Yao","year":"1999","journal-title":"Structure"},{"issue":"6","key":"10.1016\/j.vaccine.2014.03.022_bib0105","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.4049\/jimmunol.175.6.3603","article-title":"Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes","volume":"175","author":"Schulze zur Wiesch","year":"2005","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2014.03.022_bib0110","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00251-006-0185-3","article-title":"Identification of CTL epitopes in hepatitis C virus by a genome-wide computational scanning and a rational design of peptide vaccine","volume":"59","author":"Mashiba","year":"2007","journal-title":"Immunogenetics"},{"issue":"3","key":"10.1016\/j.vaccine.2014.03.022_bib0115","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1053\/jhep.2003.50115","article-title":"Novel CD4+ and CD8+ T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection","volume":"37","author":"Wertheimer","year":"2003","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.vaccine.2014.03.022_bib0120","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.hepres.2006.08.011","article-title":"Identification of novel hepatitis C virus-specific cytotoxic T lymphocyte epiotpe in NS3 region","volume":"36","author":"Ito","year":"2006","journal-title":"Hepatol Res"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2014.03.022_bib0125","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jim.2004.01.023","article-title":"The use of class-I HLA tetramers for the detection of hepatitis C virus NS3-specific CD8(+) T cells in patients with chronic infection","volume":"287","author":"L\u00f3pez-Labrador","year":"2004","journal-title":"J Immunol Methods"},{"issue":"7","key":"10.1016\/j.vaccine.2014.03.022_bib0130","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1128\/JVI.01700-07","article-title":"Analysis of the evolutionary forces in an immunodominant CD8 epitope in hepatitis C virus at a population level","volume":"82","author":"Neumann-Haefelin","year":"2008","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2014.03.022_bib0135","first-page":"883","article-title":"The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes","volume":"15","author":"Erickson","year":"2001","journal-title":"Immunology"},{"issue":"Pt 8","key":"10.1016\/j.vaccine.2014.03.022_bib0140","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1099\/vir.0.80862-0","article-title":"Hepatitis C virus NS3 protein interacts with ELKS-\u03b4 and ELKS-\u03b1, members of a novel protein family involved in intracellular transport and secretory pathways","volume":"86","author":"Hidajat","year":"2005","journal-title":"J Gen Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2014.03.022_bib0145","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.vaccine.2005.08.069","article-title":"Immunogenicity and anti-Burkholderia pseudomallei activity in Balb\/c mice immunized with plasmid DNA encoding flagellin","volume":"24","author":"Chen","year":"2006","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2014.03.022_bib0150","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1128\/IAI.70.3.1434-1442.2002","article-title":"Extracellular antigens from Salmonella enteritidis induce effective immune response in mice after oral vaccination","volume":"70","author":"Strindelius","year":"2002","journal-title":"Infect Immun"},{"issue":"2","key":"10.1016\/j.vaccine.2014.03.022_bib0155","doi-asserted-by":"crossref","first-page":"e29552","DOI":"10.1371\/journal.pone.0029552","article-title":"Immunization of mice with recombinant protein CobB or AsnC confers protection against Brucella abortus infection","volume":"7","author":"Fu","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.vaccine.2014.03.022_bib0160","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.addr.2005.12.003","article-title":"Needle-free vaccine delivery","volume":"58","author":"Giudice","year":"2006","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"10.1016\/j.vaccine.2014.03.022_bib0165","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4110\/in.2012.12.5.165","article-title":"Mucosal Immune System and M Cell-targeting Strategies for Oral Mucosal Vaccination","volume":"12","author":"Kim","year":"2012","journal-title":"Immune Netw"},{"issue":"9","key":"10.1016\/j.vaccine.2014.03.022_bib0170","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/j.vaccine.2009.12.037","article-title":"HCV-core and NS3 antigens play disparate role in inducing regulatory or effector T cells in vivo: implications for viral persistence or clearance","volume":"28","author":"Krishnadas","year":"2010","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2014.03.022_bib0175","first-page":"180","article-title":"Enhancing immunogenicity by CpG DNA","volume":"5","author":"Jiang","year":"2003","journal-title":"Curr Opin Mol Ther"},{"issue":"12","key":"10.1016\/j.vaccine.2014.03.022_bib0180","doi-asserted-by":"crossref","first-page":"7014","DOI":"10.1128\/IAI.71.12.7014-7022.2003","article-title":"Orally administered CpG oligodeoxynucleotide induces production of CXC and CC Chemokines in the gastric mucosa and suppresses bacterial colonization in a mouse model of Helicobacter pylori infection","volume":"71","author":"Raghavan","year":"2003","journal-title":"Infect Immun"},{"issue":"8","key":"10.1016\/j.vaccine.2014.03.022_bib0185","first-page":"e6130","article-title":"Construction and preparation of three recombinant adenoviruses expressing truncated NS3 and core genes of hepatitis C virus for vaccine purposes","volume":"12","author":"Hosseini","year":"2012","journal-title":"Hepat Mon"},{"issue":"12","key":"10.1016\/j.vaccine.2014.03.022_bib0190","doi-asserted-by":"crossref","first-page":"e51656","DOI":"10.1371\/journal.pone.0051656","article-title":"Immunization with a recombinant vaccinia virus that encodes nonstructural proteins of the hepatitis C virus suppresses viral protein levels in mouse liver","volume":"7","author":"Sekiguchi","year":"2012","journal-title":"PLoS One"},{"issue":"49","key":"10.1016\/j.vaccine.2014.03.022_bib0195","doi-asserted-by":"crossref","first-page":"6225","DOI":"10.1016\/j.vaccine.2008.07.052","article-title":"Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a\/1b consensus DNA vaccine","volume":"26","author":"Lang","year":"2008","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14003661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14003661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:20:13Z","timestamp":1759400413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14003661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":39,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0264410X14003661"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.03.022","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral administration of genetically modified Bifidobacterium displaying HCV-NS3 multi-epitope fusion protein could induce an HCV-NS3-specific systemic immune response in mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.03.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}